Cingulate (NASDAQ:CING) Director Peter Werth Acquires 19,455 Shares of Stock

Cingulate Inc. (NASDAQ:CING) Director Peter Werth bought 19,455 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were acquired at an average cost of $5.04 per share, for a total transaction of $98,053.20. Following the completion of the transaction, the director owned 117,449 shares of the company’s stock, valued at approximately $591,942.96. The trade was a 19.85% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cingulate Stock Performance

Shares of CING opened at $6.82 on Wednesday. Cingulate Inc. has a one year low of $3.20 and a one year high of $7.92. The stock has a 50-day moving average price of $4.92 and a 200 day moving average price of $4.30. The company has a market capitalization of $50.81 million, a P/E ratio of -1.88 and a beta of -0.75.

Cingulate (NASDAQ:CING) last announced its earnings results on Thursday, November 13th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.55). As a group, equities research analysts forecast that Cingulate Inc. will post -11.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cingulate

A number of institutional investors have recently modified their holdings of the business. Quantum Private Wealth LLC lifted its holdings in Cingulate by 140.0% in the third quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company’s stock worth $94,000 after acquiring an additional 14,000 shares during the last quarter. Soltis Investment Advisors LLC bought a new position in shares of Cingulate during the fourth quarter valued at approximately $43,000. Bank of America Corp DE raised its position in shares of Cingulate by 283.1% during the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock worth $31,000 after purchasing an additional 5,543 shares during the period. XTX Topco Ltd bought a new stake in shares of Cingulate in the 2nd quarter worth approximately $45,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Cingulate by 43.9% in the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock worth $265,000 after purchasing an additional 18,629 shares during the last quarter. Institutional investors own 41.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Cingulate in a report on Wednesday, January 21st. Roth Mkm reduced their price target on shares of Cingulate from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, November 19th. Finally, Ascendiant Capital Markets lowered their price objective on Cingulate from $62.00 to $58.00 and set a “buy” rating for the company in a report on Monday, December 8th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cingulate presently has a consensus rating of “Moderate Buy” and an average price target of $31.33.

Trending Headlines about Cingulate

Here are the key news stories impacting Cingulate this week:

• Positive Sentiment: Company insiders (CEO Shane J. Schaffer) bought 6,809 shares at ~$5.04 on Feb 6, increasing his stake >200% — a strong vote of confidence from management. Read More.
• Positive Sentiment: CFO Jennifer L. Callahan purchased 4,864 shares at ~$5.04 on Feb 6, substantially raising her position — another management buy that can be viewed as bullish. Read More.
• Positive Sentiment: EVP Matthew Brams bought 1,946 shares at ~$5.04 on Feb 6, increasing his ownership by ~72% — additional insider accumulation. Read More.
• Positive Sentiment: Director Peter J. Werth acquired 19,455 shares at ~$5.04 on Feb 6, a ~20% increase in his stake — significant dollar-sized insider purchase. Read More.
• Neutral Sentiment: A new study reports impaired brain energy metabolism in people with post-COVID — relevant to long-COVID neuroscience but only indirectly related to Cingulate unless the company ties its programs to this biology. Read More.
• Neutral Sentiment: On Feb 10 a short-interest data point shows “0 shares” (an apparent reporting glitch), which creates temporary data uncertainty for traders; treat with caution.
• Negative Sentiment: Earlier short-interest (Jan 30) rose to 389,923 shares — ~5.5% of float and a short‑ratio near 1 day — indicating active short-selling pressure that can amplify downward moves.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.